After systemic administration, they engage both GLP1R and GIPR simultaneously in native tissue, enabling the study of receptor engagement, metabolic responses, and therapeutic effects at the cellular and organ level, going beyond localization to provide functional readouts directly in living models
As a result, GLP-1 receptor agonists (GLP-1RAs) have been developed
Researchers have been particularly interested in its action on: GLP-1 receptors GIP receptors Glucagon receptors While these scientific terms may sound technical, the practical implication is easier to understand
In a separate study , published in JAMA in August 2025, the same researchers found that, across ages, GLP-1s were associated with lower risk of some obesity-related cancers, such as endometrial, ovarian, and meningioma cancers, but with an increased risk of kidney cancer, and nonsignificant changes for several other cancers